Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF Prostate Cancer Clinical Trials Consortium

BACKGROUND: Integrins mediate invasion and angiogenesis in prostate cancer bone metastases. We conducted a phase II study of Cilengitide, a selective antagonist of α(v)β(3) and α(v)β(5) integrins, in non-metastatic castration resistant prostate cancer with rising PSA. METHODS: Patients were observed...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Alva, Ajjai, Slovin, Susan, Daignault, Stephanie, Carducci, Michael, DiPaola, Robert, Pienta, Ken, Agus, David, Cooney, Kathleen, Chen, Alice, Smith, David C., Hussain, Maha
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3175265/
https://ncbi.nlm.nih.gov/pubmed/21049281
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-010-9573-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados